Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_provenance.
- NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_assertion description "[Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is treated with HER2-targeted agents, such as trastuzumab and lapatinib, that suppress signaling by phosphatidylinositol 3-kinase (PI3K)-Akt and MAPK pathways.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_provenance.
- NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_assertion evidence source_evidence_literature NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_provenance.
- NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_assertion SIO_000772 24754246 NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_provenance.
- NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_assertion wasDerivedFrom befree-2016 NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_provenance.
- NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_assertion wasGeneratedBy ECO_0000203 NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_provenance.
- befree-2016 importedOn "2016-02-19" NP1175620.RA2YlOh0deg1Om0IBsLcLujfkZ4xlpSwYvl3b6ipu87Bc130_provenance.